

BRITISH SOCIETY OF ENDOVASCULAR THERAPY
UNAUDITED
TRUSTEES' REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025

ArmstrongWatson[®]
Accountants, Business & Financial Advisers

BRITISH SOCIETY OF ENDOVASCULAR THERAPY

CONTENTS

	Page
Reference and administrative details of the Charity, its Trustees and advisers	1
Trustees' report	2 - 5
Independent examiner's report	6
Statement of financial activities	7
Balance sheet	8
Notes to the financial statements	9 - 16

BRITISH SOCIETY OF ENDOVASCULAR THERAPY

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 JANUARY 2025

Trustees

Professor B Modarai, Trustee
Mr S Neequaye, Trustee
Mr P Bevis, Trustee
Mr P Moxey, Trustee
Mr D Bosanquet, Trustee
Mr A Saratzis, Trustee (Resigned 28 June 2024)
Ms E Wilton, Trustee
Mr M Claridge, Trustee
Ms B Sandford, Trustee
Dr K Lewis, Trustee
Dr S Dindyal, Trustee
Dr A Wigham, Trustee
Mr N Dattani, Trustee
Miss K Sritharan, Trustee
Mr A Patel, Trustee (appointed 28 June 2024)
Mr S Nandhra, Trustee (appointed 28 June 2024)
Mr J McCaslin, Trustee (appointed 28 June 2024)

Charity registered number

1181623

Accountants

Armstrong Watson LLP
Carleton House
136 Gray Street
Workington
Cumbria
CA14 1LP

BRITISH SOCIETY OF ENDOVASCULAR THERAPY

TRUSTEES' REPORT FOR THE YEAR ENDED 31 JANUARY 2025

The Trustees present their annual report together with the financial statements of the Charity for the year 1 February 2024 to 31 January 2025.

Objectives and activities

a. Policies and objectives

The British Society of Endovascular Therapy's primary role is to promote the best in research, training, education and clinical practice for the benefit of people with medical conditions who could potentially be helped by endovascular therapies.

It achieves this with the following aims:

- 1) to advance health by promoting scientific research, education and training in endovascular treatment and procedures; and
- 2) to advance the education of the public and particularly amongst health professionals in endovascular treatment and procedures

The Society continues its commitment to improving the quality of endovascular surgery in the UK through its training courses, Annual Meeting, and Training and Research Fellowships.

The BSET meeting is the only dedicated UK meeting for the presentation of endovascular research. Its unique format encourages high level discussion and participation and the meeting faculty attracts the world's leading endovascular specialists.

The Society's trustees have complied with the duty in Section 4 of the Charities Act 2011 to have due regard to Public Benefit guidance published by the Charity Commission.

Achievements and performance

a. Education and Training

The Society's Annual Meeting was held in June 2024. The meeting attracted over 120 endovascular consultants, trainees and allied medical professionals. The programme comprised presentations from guest speakers from the USA, Italy, and the Netherlands, with abstract and poster presentations from endovascular trainees in the UK. The Society awards a prize for the best presented abstract in the Aortic Prize Session and Peripheral Prize Session, as well as for the best poster presentation at the Annual Meeting.

A National Vascular Training Day was held prior to the Annual Meeting for 36 junior endovascular trainees comprising small case based discussion groups and practical hands-on training on endovascular devices.

The BSET Endovascular Training Course was held in March 2024 for senior vascular and interventional radiology trainees. Attendees were taught in small group sessions looking at the finer points of endovascular treatment alongside industry who provided hands-on practical training on surgical devices.

The BSET Training Courses and Annual Meeting are well received by attendees, particularly endovascular trainees. Feedback received from the Annual Meeting includes comments that the programme content was of a high standard; that the meeting provides an excellent opportunity to get up to date practice information and new guidelines; and that it allows individuals to focus on ongoing research and training for the benefit of patients. Attendees at the Society Training Courses found that they were well structured with opportunities for peer discussion offering the greatest learning value. In particular, attendees found that the faculty's expertise and the presentations were of the highest standard, offering insightful and well-structured content that was clinically relevant.

The BSET Fellowship Programme was advertised for 2024 and one Endovascular Training Fellowship was appointed who will undertake a six month training post at Addenbrooke's Hospital, Cambridge. The Training Fellowship provides an opportunity for vascular or interventional radiology trainees to acquire new or more complex endovascular skills.

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2025**

Achievements and performance (continued)

Two Endovascular Travel Fellows were appointed, and funding was given to support further training in specialist endovascular units in Germany and Italy.

All BSET Fellows provide a written report of their Fellowship experience which is made available on the Society's website, and also attend the Annual Meeting to give a presentation to attendees.

b. Research

BSET is committed to driving excellence in research and improving outcomes for patients by raising the profile and impact of endovascular research.

Two Research Pump Priming Grants were awarded for the first time in 2024 to support research projects in the field of endovascular therapy.

The BSET-Conformable EndoVascular Aneurysm Registry, on behalf of Gore, commenced in 2019. The primary objective of the registry is to collect real-world clinical data and device specific outcomes of GORE EXCLUDER Conformable AAA Endoprosthesis in routine clinical treatment of patients with abdominal aortic aneurysms. All data checks on 12 month follow-up clinical data have been analysed and a manuscript "An analysis of aortic neck coverage of the GORE® EXCLUDER® Conformable AAA Endoprosthesis with ACTIVE CONTROL System," has been accepted for publication in the Journal of Endovascular Therapy.

BSET has supported new research evaluating long-term outcomes (>10 years) for FEVAR from GLOBALSTAR registry data (Global Collaborators on Advanced Stent-Graft Techniques for Aneurysm Repair). The registry originally contained 881 records from 15 collaborating centres. The aim of the present study is to complete long-term follow-up for GLOBALSTAR by collecting new data and bolstering study numbers through the contribution of new retrospective cases with accrued follow-up data from participating centres. The ethical approval for GLOBALSTAR was renewed by the current study team. The team is led by Chief Investigator for GLOBALSTAR, Mr Simon Neequaye (Trustee) and co-investigator Mr Aurélien Guérault at St George's Hospital. The co-investigator has come out of programme for a doctoral thesis. The hospital agreed to meet the cost of this and so the Trustees agreed that the funds set aside as restricted for Globalstar could now be made unrestricted funds. Any expenses incurred to support the work of the researcher would be paid for from these funds.

The project has benefited from patient involvement/feedback through the St George's Vascular patient advisory group. Upon integration of the final centre's dataset, manuscript writing will begin. Results will be disseminated through academic conferences and the data will be presented at the Annual Meeting in June 2025. It is hoped that publication of the final data will positively influence commissioning decisions within the NHS.

c. Collaborative work

Discussions had taken place with the British Society of Interventional Radiology with the aim to form a closer relationship between BSET and BSIR. A statement of collaboration was produced and an agreement made to have an educational session at the BSIR Annual Meeting. It was also agreed to pursue a joint educational webinar.

The Trustees were working with the charity The Circulation Foundation to assist with an update on their patient information leaflets relating to endovascular treatment.

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2025**

Achievements and performance (continued)

d. Structure, governance and management

Two Trustee meetings were held in person and two on-line during this period. Organisational matters were dealt with via email.

The Trustees had agreed to introduce a new role of Vice-President. The Vice-President was elected in June 2024 and commenced a one year lead-in period prior to taking on the role as President for two years from June 2025. This position is open to all previous and current Council members of BSET.

Two new Trustees were elected in June 2024.

The Trustees continued to discuss the need for a policy on equality, diversity and inclusion and work was continuing on this.

e. Aims and key objectives for future periods

The Trustees plan to continue to hold the Endovascular Training Course in March 2025, and also hold the Annual Meeting and National Vascular Training Day in June 2025. Consideration would be given to extending the length of the Annual Meeting.

An Endovascular Training Fellowship and Travel Fellowship(s) will be offered in 2025. Consideration would be given to increasing the amount awarded for a Travel Fellowship.

A Research Pump Priming Grant will be awarded to support a research project in the field of endovascular therapy. Consideration would be given to increasing the level of the grant with the option of awarding up to two grants.

The Trustees will continue to work with the charity The Circulation Foundation to update their patient information leaflets relating to endovascular treatment.

Discussions will continue with the British Society of Interventional Radiology with the aim to form a closer relationship between BSET and BSIR to involve increased participation of Society members at both meetings and increased dialogue.

Financial review

a. Reserves policy

The Society's reserves policy is maintained at £280,000. This will allow BSET to keep approximately 2 years' annual operating costs in reserve. The Trustees will continue to assess the level of reserves it requires and will update the policy if it is felt its financial requirements have changed.

The reserves policy ensures unrestricted funds are sufficient to meet two years' activity of the Society, to cover:

- a) The risk of unforeseen emergency or other unexpected need for funds, e.g. to provide 'seed-funding' for an urgent project.
- b) Unforeseen day-to-day operational costs, e.g. employing temporary staff to cover a long-term sick absence.
- c) A source of income, e.g. a sponsorship of our meetings, not being renewed. Funds might be needed to give the trustees time to take action if income falls below expectations.
- d) The need to fund short-term deficits in a cash budget, e.g. money may need to be spent before a funding grant is received.

BRITISH SOCIETY OF ENDOVASCULAR THERAPY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 JANUARY 2025

Structure, governance and management

a. Methods of appointment or election of Trustees

Every trustee is appointed for a term of three years. In selecting individuals for appointment, the charity trustees must have regard to the skills, knowledge and experience needed for the effective administration of the CIO. Individuals are requested to submit a 200 word personal statement outlining why they wish to act as a charity trustee.

All new trustees are asked to sign a statement of eligibility and are sent the following:

- The charity's constitution
- The minutes of Council meetings for the previous year;
- List of current trustees and contact details;
- Annual list of dates of trustee meetings;
- The most recent Charity accounts;
- A copy of the Charity Commission publication 'The Essential Trustee – What you need to know';

There are four trustee (Council) meetings a year at which operational and financial matters of the Society are discussed, and strategic decisions about the direction of the charity are taken.

In between meetings, decisions are made by telephone or e-mail communication between the Honorary Officers and other trustees.

An administrator working on a consultancy basis deals with matters pertaining to the general organisation of the Society, Annual Meeting and other events.

BSET has collaborative links with the Royal College of Surgeons (Eng), Royal College of Surgeons (Ed), the Vascular Society of Great Britain and Ireland, the Rouleaux Club, the British Society of Interventional Radiology, and the BSIR Trainees to help further the aims of the developing speciality and to deliver high standards of practice.

Approved by order of the members of the board of Trustees and signed on their behalf by:



Professor B Modarai



Mr P Bevis

Date: 25 June 2025

BRITISH SOCIETY OF ENDOVASCULAR THERAPY

**INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 31 JANUARY 2025**

Independent examiner's report to the Trustees of British Society of Endovascular Therapy ('the Charity')

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 31 January 2025.

Responsibilities and basis of report

As the Trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

I report in respect of my examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Your attention is drawn to the fact that the Charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed:



Steven Kirkbride

Dated: 11.07.25.

BFP FCA ATT MAAT

Armstrong Watson LLP - Workington

BRITISH SOCIETY OF ENDOVASCULAR THERAPY

STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 JANUARY 2025

	Note	Unrestricted funds 2025 £	Restricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
Income from:					
Donations and legacies	3	-	35,988	35,988	68,964
Other trading activities	4	166,571	-	166,571	294,644
Investments	5	956	-	956	-
Other income	6	30,998	-	30,998	26,299
Total income		198,525	35,988	234,513	389,907
Expenditure on:					
Charitable activities		164,551	775	165,326	310,609
Total expenditure		164,551	775	165,326	310,609
Net income		33,974	35,213	69,187	79,298
Transfers between funds	10	100,644	(100,644)	-	-
Net movement in funds		134,618	(65,431)	69,187	79,298
Reconciliation of funds:					
Total funds brought forward		374,100	65,431	439,531	360,233
Net movement in funds		134,618	(65,431)	69,187	79,298
Total funds carried forward		508,718	-	508,718	439,531

The Statement of financial activities includes all gains and losses recognised in the year.

The notes on pages 9 to 16 form part of these financial statements.

BRITISH SOCIETY OF ENDOVASCULAR THERAPY

BALANCE SHEET
AS AT 31 JANUARY 2025

	Note	2025 £	2024 £
Fixed assets			
		-	-
Current assets			
Cash at bank and in hand		510,398	441,061
		510,398	441,061
Creditors: amounts falling due within one year	9	(1,680)	(1,530)
Net current assets		508,718	439,531
Total assets less current liabilities		508,718	439,531
Net assets excluding pension asset		508,718	439,531
Total net assets		508,718	439,531
Charity funds			
Restricted funds	10	-	65,431
Unrestricted funds	10	508,718	374,100
Total funds		508,718	439,531

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:


Professor B. Modarai


Mr P. Bevis

Date: 25 June 2025

The notes on pages 9 to 16 form part of these financial statements.

BRITISH SOCIETY OF ENDOVASCULAR THERAPY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025

1. General information

British Society Of Endovascular Therapy is a charitable incorporated organisation.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

British Society of Endovascular Therapy meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

2.3 Income

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Other income is recognised in the period in which it is receivable and to the extent the goods have been provided or on completion of the service.

2.4 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.

All expenditure is inclusive of irrecoverable VAT.

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025**

2. Accounting policies (continued)

2.5 Taxation

The Charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

2.6 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.7 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of financial activities as a finance cost.

2.8 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2.9 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

BRITISH SOCIETY OF ENDOVASCULAR THERAPY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025

3. Income from donations and legacies

	Restricted funds 2025 £	Total funds 2025 £
CLEVAR income	35,988	35,988

	<i>Restricted funds 2024 £</i>	<i>Total funds 2024 £</i>
CLEVAR income	68,964	68,964

4. Income from other trading activities

Income from fundraising events

	Unrestricted funds 2025 £	Total funds 2025 £
Annual meeting registration	44,571	44,571
Sponsorships	122,000	122,000
	166,571	166,571

	<i>Unrestricted funds 2024 £</i>	<i>Total funds 2024 £</i>
Annual meeting registration	38,644	38,644
Sponsorships	256,000	256,000
	294,644	294,644

BRITISH SOCIETY OF ENDOVASCULAR THERAPY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025

5. Investment income

	Unrestricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
Investment income	956	956	-

6. Other incoming resources

	Unrestricted funds 2025 £	Total funds 2025 £
Spring course income	28,557	28,557
Other income	2,441	2,441
	30,998	30,998

	Unrestricted funds 2024 £	Total funds 2024 £
Spring course income	24,595	24,595
Other income	1,704	1,704
	26,299	26,299

7. Analysis of expenditure by activities

	Activities undertaken directly 2025 £	Total funds 2025 £
Charitable activities	165,326	165,326

BRITISH SOCIETY OF ENDOVASCULAR THERAPY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025

7. Analysis of expenditure by activities (continued)

	<i>Activities undertaken directly 2024 £</i>	<i>Total funds 2024 £</i>
Charitable activities	310,609	310,609

Analysis of direct costs

	Activities 2025 £	Total funds 2025 £
Annual meeting costs	94,402	94,402
Sundry expenses	1,736	1,736
Travel and subsistence	1,752	1,752
Spring course expenditure	15,996	15,996
Accountancy fees	1,840	1,840
Consultancy fees	26,883	26,883
Bank charges	165	165
Postage, printing and stationery	1,177	1,177
Prizes and bursaries	600	600
Fellowship	10,000	10,000
Pump priming award expenditure	10,000	10,000
Globalstar expenditure	775	775
	165,326	165,326

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025**

7. Analysis of expenditure by activities (continued)

Analysis of direct costs (continued)

	<i>Activities 2024 £</i>	<i>Total funds 2024 £</i>
Annual meeting costs	105,837	105,837
Sundry expenses	3,271	3,271
Travel and subsistence	1,309	1,309
Spring course expenditure	38,354	38,354
Accountancy fees	1,608	1,608
Consultancy fees	28,359	28,359
Bank charges	133	133
Postage, printing and stationery	566	566
Prizes and bursaries	688	688
CLEVAR expenditure	75,498	75,498
Fellowship	54,481	54,481
Globalstar expenditure	505	505
	<u>310,609</u>	<u>310,609</u>

8. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2024 - £NIL).

During the year ended 31 January 2025, no Trustee expenses have been incurred (2024 - £NIL).

9. Creditors: Amounts falling due within one year

	2025 £	2024 £
Accruals and deferred income	<u>1,680</u>	<u>1,530</u>

BRITISH SOCIETY OF ENDOVASCULAR THERAPY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025

10. Statement of funds

Statement of funds - current year

	Balance at 1 February 2024 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 January 2025 £
Unrestricted funds					
General Funds - all funds	374,100	198,525	(164,551)	100,644	508,718
Restricted funds					
BSET CLEAVAR	17,736	35,988	-	(53,724)	-
Globalstar	47,695	-	(775)	(46,920)	-
	65,431	35,988	(775)	(100,644)	-
Total of funds	439,531	234,513	(165,326)	-	508,718

Statement of funds - prior year

	Balance at 1 February 2023 £	Income £	Expenditure £	Balance at 31 January 2024 £
Unrestricted funds				
General Funds - all funds	287,763	320,943	(234,606)	374,100
Restricted funds				
BSET CLEVAR	24,270	68,964	(75,498)	17,736
Globalstar	48,200	-	(505)	47,695
	72,470	68,964	(76,003)	65,431
Total of funds	360,233	389,907	(310,609)	439,531

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025**

11. Analysis of net assets between funds

Analysis of net assets between funds - current period

	Unrestricted funds 2025 £	Restricted funds 2025 £	Total funds 2025 £
Current assets	456,674	53,724	510,398
Creditors due within one year	(1,680)	-	(1,680)
Difference	53,724	(53,724)	-
Total	508,718	-	508,718

Analysis of net assets between funds - prior period

	<i>Unrestricted funds 2024 £</i>	<i>Restricted funds 2024 £</i>	<i>Total funds 2024 £</i>
Current assets	375,630	65,431	441,061
Creditors due within one year	(1,530)	-	(1,530)
Total	374,100	65,431	439,531

12. Related party transactions

The Charity has not entered into any related party transaction during the year, nor are there any outstanding balances owing between related parties and the Charity at 31 January 2025.